Psychiatric risk profile of apremilast
PDF
Cite
Share
Request
Letter to the Editor
P: 87-89
July 2024

Psychiatric risk profile of apremilast

J Turk Soc Rheumatol 2024;16(2):87-89
No information available.
No information available
Received Date: 01.05.2024
Accepted Date: 10.06.2024
Online Date: 22.07.2024
Publish Date: 22.07.2024
PDF
Cite
Share
Request

References

1
Fala L. Otezla (Apremilast), an Oral PDE-4 Inhibitor, Receives FDA Approval for the Treatment of Patients with Active Psoriatic Arthritis and Plaque Psoriasis. Am Health Drug Benefits. 2015;8(Spec Feature):105-10.
2
Kavanaugh A, Mease PJ, Gomez-Reino JJ, et al. Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor. Ann Rheum Dis. 2014;73:1020-6.
3
Hatemi G, Mahr A, Ishigatsubo Y, et al. Trial of Apremilast for Oral Ulcers in Behçet’s Syndrome. N Engl J Med. 2019;381:1918-28.
4
Rich P, Gooderham M, Bachelez H, et al. Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with difficult-to-treat nail and scalp psoriasis: Results of 2 phase III randomized, controlled trials (ESTEEM 1 and ESTEEM 2). J Am Acad Dermatol. 2016;74:134-42.
5
Schett G, Wollenhaupt J, Papp K, et al. Oral apremilast in the treatment of active psoriatic arthritis: results of a multicenter, randomized, double-blind, placebo-controlled study. Arthritis Rheum. 2012;64:3156-67.
6
Cutolo M, Myerson GE, Fleischmann RM, et al. A Phase III, Randomized, Controlled Trial of Apremilast in Patients with Psoriatic Arthritis: Results of the PALACE 2 Trial. J Rheumatol. 2016;43:1724-34.
7
Edwards CJ, Blanco FJ, Crowley J, et al. Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement: a phase III, randomised, controlled trial (PALACE 3). Ann Rheum Dis. 2016;75:1065-73.
8
Mease PJ, Gladman DD, Gomez-Reino JJ, et al. Long-Term Safety and Tolerability of Apremilast Versus Placebo in Psoriatic Arthritis: A Pooled Safety Analysis of Three Phase III, Randomized, Controlled Trials. ACR Open Rheumatol. 2020;2:459-70.
9
Reich K, Gooderham M, Green L, et al. The efficacy and safety of apremilast, etanercept and placebo in patients with moderate-to-severe plaque psoriasis: 52-week results from a phase IIIb, randomized, placebo-controlled trial (LIBERATE). J Eur Acad Dermatol Venereol. 2017;31:507-17.
10
Ohtsuki M, Okubo Y, Komine M, et al. Apremilast, an oral phosphodiesterase 4 inhibitor, in the treatment of Japanese patients with moderate to severe plaque psoriasis: Efficacy, safety and tolerability results from a phase 2b randomized controlled trial. J Dermatol. 2017;44:873-84.
11
Mrowietz U, Barker J, Conrad C, et al. Efficacy and safety of apremilast in patients with limited skin involvement, plaque psoriasis in special areas and impaired quality of life: Results from the EMBRACE randomized trial. J Eur Acad Dermatol Venereol. 2023;37:348-55.
12
Wells AF, Edwards CJ, Kivitz AJ, et al. Apremilast monotherapy for long-term treatment of active psoriatic arthritis in DMARD-naïve patients. Rheumatology (Oxford). 2022;61:1035-43.
13
Hatemi G, Mahr A, Takeno M, et al. Apremilast for oral ulcers associated with active Behçet’s syndrome over 68 weeks: long-term results from a phase 3 randomised clinical trial. Clin Exp Rheumatol. 2021;39(Suppl 132):80-7.
14
Vasilakis-Scaramozza C, Persson R, Hagberg KW, Jick S. The risk of treated anxiety and treated depression among patients with psoriasis and psoriatic arthritis treated with apremilast compared to biologics, DMARDs and corticosteroids: a cohort study in the United States MarketScan database. J Eur Acad Dermatol Venereol. 2020;34:1755-63.
15
Mease PJ, Hatemi G, Paris M, et al. Apremilast Long-Term Safety Up to 5 Years from 15 Pooled Randomized, Placebo-Controlled Studies of Psoriasis, Psoriatic Arthritis, and Behçet’s Syndrome. Am J Clin Dermatol. 2023;24:809-20.
16
De Luca G, Cariddi A, Campochiaro C, et al. Efficacy and safety of apremilast for Behçet’s syndrome: a real-life single-centre Italian experience. Rheumatology (Oxford). 2020;59:171-5.
17
Atienza-Mateo B, Martín-Varillas JL, Graña J, et al. Apremilast in refractory orogenital ulcers and other manifestations of Behçet’s disease. A national multicentre study of 51 cases in clinical practice. Clin Exp Rheumatol. 2020;38(Suppl 127):69-75.
18
Vieira M, Buffier S, Vautier M, et al. Apremilast in Refractory Behçet’s Syndrome: A Multicenter Observational Study. Front Immunol. 2021;11:626792.
19
de Vlam K, Toukap AN, Kaiser MJ, et al. Real-World Efficacy and Safety of Apremilast in Belgian Patients with Psoriatic Arthritis: Results from the Prospective Observational APOLO Study. Adv Ther. 2022;39:1055-67.
20
Available from:https://www.ema.europa.eu/en/medicines/human/EPAR/otezla.
21
Cowan TL, Wilson A, Murrell DF. Mental health, insomnia and suicidal ideation during treatment with apremilast. Australas J Dermatol. 2022;63:403-4.
22
https://titck.gov.tr/storage/Archive/2022/dynamicModulesAttachment/ApremilastUygulamaBasamaklar_dd3a39fa-1990-4bd5-a481-ffc173a96d25.pdf